IMGN News and Press, ImmunoGen Inc. From 05/06/22

ImmunoGen press release (NASDAQ:IMGN): Q1 GAAP EPS of -$0.10 beats by $0.11. Revenue of $38.08M (+142.5% Y/Y) beats by $17.24M. FY2022 outlook remains unchanged: Revenues between $75M and $85M vs. consensus of $84.98M; Operating expenses between $285Mand $295M; Cash and cash equivalents ...

Submitted BLA for Mirvetuximab Soravtansine Monotherapy to FDA Under Accelerated Approval Pathway; Commercial Preparations Underway Presented Results from Positive Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer in Plenary Session at SGO Annual Meeting; Add...

ImmunoGen (NASDAQ:IMGN) is scheduled to announce Q1 earnings results on Friday, May 6th, before market open. The consensus EPS Estimate is -$0.21 (-1150.0% Y/Y) and the consensus Revenue Estimate is $20.84M (+32.7% Y/Y). Over the last 3 months, EPS estimates have seen 4 upward revisions and 2...

Palm Beach, FL – April 25, 2022 – FinancialNewsMedia.com News Commentary – The formation of mutational cells or tissues in female reproductive organs called ovaries leads to ovarian cancer. Cancer remains undetected until the mutation spreads to the stomach ...

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, May 6, 2022 to discuss its first quarter 2022 operating results. Man...

Volatility remains the dominant factor across the equities market, with interest rates rising and growth stocks well underwater so far in 2022. Ground zero for this correction is among “long duration assets”, which includes growth stocks with big hypothetical cash flows down the...

The market recently discounted ImmunoGen due to its expectation of Mirvetuximab's SORAYA data. Contrary to market belief, I view Mirve as a stellar drug for the treatment of advanced ovarian cancer. I forecast a high likelihood of upcoming Mirve approval. For further details...

Gainers: SPI Energy (SPI) +36%. Workday (WDAY) +11%. TMC the metals company (TMC) +10%. ThredUp (TDUP) +7%. WAVE Life Sciences (WVE) +4%. Losers: CRISPR Therapeutics (CRSP) -7%. ImmunoGen (IMGN) -5%. Ionis Pharmaceuticals (IONS) -5%. Radius Health (RDUS) -5%. Fluidigm (FLDM) -4%. ...

With ImmunoGen (NASDAQ: IMGN) shares sliding by more than 39% in the past 12 months, its investors are bound to be looking for salvation. What's more, despite recent clinical trial results that management hailed as positive, the biotech's stock just might continue to struggle in the...

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Dr. Anna Berkenblit, Chief Medical Officer, will participate in the Reshaping Ovarian Cancer panel discussion at the upcoming Canaccor...